In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...

Stock analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March ...

Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK PLC closed 18.56% short of its 52-week high of £18.24, which the company achieved on May 16th.